SiSaf Revenue and Competitors

SiSaf is the first company to develop Bio-Courier® platform technology, a highly tailored approach that advances drug delivery into the age of personalized, precision medicine. Bio-Couriers leverage the unique properties of bioabsorbable elemental silicon (14Si) hybrids for non-viral, in-vivo gene-based therapies focused on autosomal dominate disorders. Unlike viral vectors and narrow focused non-viral delivery vehicles, Bio-Courier technology can load and protect high quantities of nucleic acids (siRNA, mRNA and DNA) which are delivered to the cytosol bypassing endosomal uptake and degradation. Furthermore the particles may be coated with targeting peptides for delivery to specific cell populations. Bio-Courier technology provides unsurpassed versatility, safety and efficiency that enables topical, systemic, and repeat administration. These unique attributes coupled with a scaled, cost efficient manufacturing process will permit broad access to safe and effective gene-based therapy for numerous autosomal dominant disorders, cost effectively.